The objective of The University of Texas M. D. Anderson Cancer Center (UTMDACC) SPORE in Brain Cancer is to develop a robust translational research program with an emphasis on innovative treatments based on combinations of agents, molecularly-based diagnosis, and therapy monitoring, through which significant impact on the care of patients with malignant brain tumors will be achieved. UTMDACC has established the elimination of brain tumors as a priority and has made significant investments in this goal through establishment of a Brain Tumor Center and a Multidisciplinary Research Program to support training and research across several departmental boundaries, including neuro-oncology, neuro-surgery, neuro-pathology, diagnostic imaging, radiation oncology, epidemiology, molecular therapeutics, molecular genetics, molecular biology, pediatrics, and statistics. With this support, we have successfully organized an efficient and productive infrastructure that forms the basis for this SPORE. The translational research in this application is based on recent insights into the molecular basis of brain tumors and aims to translate these findings into innovative approaches to improve molecular diagnosis so that patients receive the therapy most likely to be benefit them, permit early evaluation of response to targeted treatment, and establish new and effective treatments based on oncolytic viruses and small molecule signal transduction inhibitors. The focus of the four Projects is described below: Project 1: Test a targeted oncolytic adenovirus, Delta-24-RGD in the clinic, and improve it by combining it with temozolomide and by delivery with mesenchymal stem cells. Project 2: Test PI3K inhibitor PX-866 in the clinic and develop rational combination therapies based on it. Project 3: Develop a molecular biomarker panel capable of identifying patients not likely to benefit from standard therapy, test it in the RTOG-0525 clinical trial with over 800 patients, and identify novel targets in the treatment of resistant tumors to support new therapy development. Project 4: Explore genetic predictors of neurocognitive and clinical outcome in glioblastoma patients. Five Cores (Administrative, Pathology and Tissue Procurement, Biostatistics, Clinical and Animal) will support the Projects, Career Development Program, and Developmental Research Program. It is imperative that we aggressively undertake translational research, as is embodied in this proposal to develop more effective approaches for patients with brain cancer;there are no effective treatment approaches for this patient population, and this SPORE guarantees that all of the resources of the UTMDACC Brain Tumor Research Program, as well as the considerable resources of the entire institution, will be brought to bear on this important public health problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA127001-04
Application #
8138385
Study Section
Special Emphasis Panel (ZCA1-GRB-I (J1))
Program Officer
Arnold, Julia T
Project Start
2008-09-01
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
4
Fiscal Year
2011
Total Cost
$2,185,000
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Neurology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Figueroa, Javier; Phillips, Lynette M; Shahar, Tal et al. (2017) Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. Cancer Res 77:5808-5819
Narang, Shivali; Kim, Donnie; Aithala, Sathvik et al. (2017) Tumor image-derived texture features are associated with CD3 T-cell infiltration status in glioblastoma. Oncotarget 8:101244-101254
Carstens, Julienne L; Correa de Sampaio, Pedro; Yang, Dalu et al. (2017) Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer. Nat Commun 8:15095
Hu, Jingzhe; Salzillo, Travis C; Sailasuta, Napapon et al. (2017) Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization. Top Magn Reson Imaging 26:27-32
Lehrer, Michael; Bhadra, Anindya; Ravikumar, Visweswaran et al. (2017) Multiple-response regression analysis links magnetic resonance imaging features to de-regulated protein expression and pathway activity in lower grade glioma. Oncoscience 4:57-66
Koul, Dimpy; Wang, Shuzhen; Wu, Shaofang et al. (2017) Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma. Oncotarget 8:21741-21753
Qian, Xu; Li, Xinjian; Cai, Qingsong et al. (2017) Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy. Mol Cell 65:917-931.e6
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2017) Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23:2891-2904
Gressot, Loyola V; Doucette, Tiffany; Yang, Yuhui et al. (2017) Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma. Oncotarget 8:12695-12704
Jiang, Hong; Rivera-Molina, Yisel; Gomez-Manzano, Candelaria et al. (2017) Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77:3894-3907

Showing the most recent 10 out of 208 publications